# Government Business Division Policies and Procedures

Section (Primary Department)		SUBJECT (Document Title) Louisiana Compound Coverage				
Pharmacy Dept			Louisiana Compound C	Loverage		
Effective Date	Date of Last	Review	Date of Last Revision	Dept. Approval Date		
08/01/2020				03/13/2020		
Department Approval/Signature :						
	<del>-</del>					
Policy applies to health plans operating in the following State(s). Applicable products noted below.						
<u>Products</u>	☐ Arkansas	☐ Indiana	☐ Nevada	☐ Tennessee		
	☐ California	$\square$ lowa	☐ New Jersey	☐ Texas		
☐ Medicare/SNP	□ Colorado	$\square$ Kentuck	xy □ New York – Empire	e 🗆 Virginia		
☐ MMP/Duals	☐ District of Columbia		na □ New York (WNY)	$\square$ Washington		
	☐ Florida	☐ Marylar	nd 🗆 North Carolina	☐ Wisconsin		
	$\square$ Georgia	☐ Minnes	ota 🗆 South Carolina	☐ West Virginia		

#### **POLICY:**

Louisiana implemented a State Preferred Drug List (PDL) on 05/01/2019. This required that all MCO's fully align with Fee-For-Service drug-utilization review and point-of-sale edits and other covered benefits. To better align with FFS, ensure appropriate use, and combat compound fraud, waste, and abuse (i.e. foot baths), Healthy Blue will update our compound coverage policy.

### **DEFINITIONS:**

**Fraud** – As relates to Medicaid Program Integrity, an intentional deception or misrepresentation made by a person with the knowledge that the deception could result in some unauthorized benefit to him or some other person. It includes any act that constitutes fraud under applicable federal or state law. Fraud may include deliberate misrepresentation of need or eligibility; providing false information concerning costs or conditions to obtain reimbursement or certification; or claiming payment for services which were never delivered or received.

**Preferred Drug List (PDL)** – a list maintained by the Louisiana Department of Health (LDH) indicating which drugs providers are permitted to prescribe without seeking prior authorization.

**Prior Authorization** – The process of determining medical necessity for specific services before they are rendered.

#### **PROCEDURE:**

Compounds that meet the following criteria will process at point of sale without prior authorization when:

- Member is age 5 & under AND
- Total reimbursement to pharmacy is less than \$200 for the compound AND

## Government Business Division Policies and Procedures

Section (Primary Department)	SUBJECT (Document Title)	
Pharmacy Dept	Louisiana Compound Coverage	

 The active ingredient national drug code (NDC) is available without prior authorization (PA) on the Louisiana Department of Health (LDH) PDL

All compound requests exceeding the above parameters will require PA. The PA team will review these requests for medical necessity. Prior authorization for the prescribed compound prescriptions will be granted when the following approval criteria has been met:

- Prescriber must provide clinical rationale or medical justification for use, including, but not limited to:
  - Request includes documentation of previous trial and failure of commercially available therapeutic alternatives
  - Request includes documentation of commercially available products are unsuitable for use
  - No reasonable therapeutic alternative(s)
  - o Supporting literature or link if applicable if needed
  - Active ingredient is a payable NDC on the PDL
  - Active ingredient is Federal Drug Administration (FDA) approved for indication
  - Active ingredient is Centers for Medicaid & Medicare Services (CMS) rebate eligible

#### **REFERENCES:**

Louisiana Medicaid Statement of Work effective date 01/01/2020 - section 6.3.2.3

#### **RESPONSIBLE DEPARTMENTS:**

#### **Primary Department:**

**Pharmacy Department** 

#### Secondary Department(s):

IngenioRx- Prior Authorization department

#### **EXCEPTIONS:**

There are currently no exceptions to this policy

#### **REVISION HISTORY:**

# Government Business Division Policies and Procedures

Section (Primary Department)	SUBJECT (Document Title)	
Pharmacy Dept	Louisiana Compound Coverage	

Review Date	Changes	
03/13/2020	New Policy and Procedure	
	•	
	•	
	•	